Microbix to Announce Q2 Fiscal 2024 Results

On May 8, 2024, Microbix Biosystems Inc., a prominent life sciences company based in Mississauga, Ontario, announced its plans to release financial statements along with management's discussion and analysis for the second quarter of fiscal 2024, which ended on March 31, 2024. This release is scheduled to occur before the commencement of trading on May 15, 2024. Following the release, Microbix is set to host a webinar at 10:00 AM ET on the same day to discuss the financial results. The webinar will feature presentations from the company’s CEO, CFO, and COO.

Investors and shareholders interested in participating in the webinar can register through a link provided by Adelaide Capital. Additionally, the session will be live-streamed on YouTube. For those unable to attend, a replay of the webinar will be accessible on Adelaide Capital’s YouTube channel.

Microbix Biosystems Inc. specializes in producing proprietary biological products aimed at enhancing human health. The company employs over 100 skilled professionals and generates revenues nearing C$ 2.0 million monthly. It manufactures a variety of essential components and devices for the global diagnostics industry, including antigens for immunoassays and laboratory quality assessment products (QAPs™). These QAPs are crucial for clinical lab proficiency testing, assay development, validation, and maintaining the quality of clinical diagnostic workflows. Microbix’s antigens are integral to the antibody tests produced by around 100 diagnostics manufacturers, and its QAPs are distributed to clinical lab accreditation organizations, diagnostics firms, and clinical labs across more than 30 countries through an international distributor network.

The company holds several significant accreditations and registrations, including ISO 9001 & 13485, U.S. FDA, Australian TGA, and a Health Canada establishment license. Additionally, Microbix offers CE-marked products, signifying compliance with European health, safety, and environmental protection standards.

Beyond its primary product line, Microbix leverages its biological expertise and infrastructure to develop other proprietary products and technologies. Notably, it produces Kinlytic® urokinase, a drug used to dissolve blood clots, and various reagents or media supporting molecular diagnostic testing, such as the DxTM™ collection device for patient samples.

Microbix Biosystems Inc. is publicly traded on both the Toronto Stock Exchange (TSX) under the symbol MBX and on the OTCQX market under the symbol MBXBF. The company’s headquarters are located in Mississauga, Ontario, Canada.

The forthcoming financial release and accompanying webinar represent a critical opportunity for stakeholders to gain insights into the company’s financial health and strategic direction. Through these efforts, Microbix aims to maintain transparency with its investors and shareholders, fostering a better understanding of the company’s performance and future prospects.